Evidence map›Paper›PMID 25928531›Full record

ArticleOrphanet journal of rare diseases2014

Molecular characterization of subcutaneous panniculitis-like T-cell lymphoma reveals upregulation of immunosuppression- and autoimmunity-associated genes.

Pilvi Maliniemi, Sonja Hahtola, Kristian Ovaska, Leila Jeskanen, Liisa Väkevä, Kirsi Jäntti, Rudolf Stadler, David Michonneau, Sylvie Fraitag, Sampsa Hautaniemi and 1 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Orphanet journal of rare diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Clinical analysis of 10 cases with subcutaneous panniculitis-like T-cell lymphoma and tissue AURKA expression.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Pilvi MaliniemiDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. pilvi.maliniemi@helsinki.fi.
Sonja HahtolaDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. sonja.hahtola@helsinki.fi.
Kristian OvaskaSystems Biology Laboratory, Institute of Biomedicine and Genome-Scale Biology Program, University of Helsinki, Helsinki, Finland. kristian.ovaska@helsinki.fi.
Leila JeskanenDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. leila.jeskanen@hus.fi.
Liisa VäkeväDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. liisa.vakeva@hus.fi.
Kirsi JänttiDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. kirsi.niiranen@helsinki.fi.
Rudolf StadlerJohannes-Wesling-Klinikum Minden, Akademisches Lehrkrankenhaus der Medizinischen Hochschule Hannover, Minden, Germany. Rudolf.Stadler@muehlenkreiskliniken.de.
David MichonneauInstitut Pasteur, Département d'immunologie, Equipe Dynamique des réponses immunes, 25 rue du Docteur Roux, 75015, Paris, France. david.michonneau@pasteur.fr.
Sylvie FraitagService d'anatomie et de cytologie pathologiques, Hôpital Necker-Enfants-Malades, AP-HP, 149, rue de Sèvres, 75743, Paris Cedex 15, France. sylvie.fraitag@nck.aphp.fr.
Sampsa HautaniemiSystems Biology Laboratory, Institute of Biomedicine and Genome-Scale Biology Program, University of Helsinki, Helsinki, Finland. sampsa.hautaniemi@helsinki.fi.
Annamari RankiDepartment of Dermatology and Allergology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. annamari.ranki@hus.fi.
Helsinki University Hospital · FIUniversity of Helsinki · FIHôpital Necker-Enfants Malades · FRInstitut Pasteur · FRMedizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSubcutaneous panniculitis-like T cell lymphomas represent a rare and difficult to diagnose entity of cutaneous T cell lymphomas. SPTL affects predominantly young adults and presents with multifocal subcutaneous nodules and frequently associated autoimmune features. The pathogenesis of SPTL is not completely understood.

methodsThe aim of this study was to unravel molecular pathways critical to the SPTL pathogenesis. Therefore, we analyzed 23 skin samples from 20 newly diagnosed SPTL patients and relevant control samples of adipose and non-malignant panniculitis tissue by using gene expression microarray, quantitative PCR, and two-colour immunohistochemistry.

resultsInterestingly, indoleamine 2,3-dioxygenase (IDO-1), an immunotolerance-inducing enzyme, was among the most highly overexpressed genes in all comparisons. The expression of Th1-specific cytokines, known to be associated with autoimmune inflammation (i.e. IFNG, CXCR3, CXCL9, CXCL10, CXCL11, and CCL5), were also significantly increased. Confirmed using immunohistochemistry, the morphologically malignant lymphocytes expressed CXCR3 and CXCL9. IDO-1 expression was found both in some morphologically malignant lymphocytes rimming the adipocytes and in surrounding CD11c(-) CD68(-) cells but not in CD11c(+) dendritic cells in the microenvironment. The proportion of FoxP3+ cells in SPTL exceeded that in the benign panniculitis samples.

conclusionsOur results indicate that the up regulation of the tolerogenic IDO-1 together with the up regulation of IFNG, CXCR3 ligands, and CCL5 are features of SPTL lesions. We anticipate that the IFNG-inducible IDO-1 expression contributes to the formation of an immunosuppressive microenvironment, favorable for the malignant T cells. This study provides a relevant molecular basis for further studies exploring novel therapeutic means for subcutaneous T cell lymphoma.

Indexed as

AdolescentAdultAgedAutoimmunityChemokine CXCL9Chemokines, CXCCytokinesFemaleHumansImmune ToleranceImmunohistochemistryIndoleamine-Pyrrole 2,3,-DioxygenaseLymphoma, T-CellMaleMiddle AgedOligonucleotide Array Sequence AnalysisChemokine CXCL9Chemokines, CXCCXCL3 protein, humanCXCL9 protein, humanCytokinesIDO1 protein, humanIndoleamine-Pyrrole 2,3,-Dioxygenase

Identifiers

PMID25928531
PMCPMC4320460
OpenAlexW2134710404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.